Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis

International Journal of Antimicrobial Agents

Volumn 36, Issue 2, 2010, Pages 159-163

  Tempone, André Gustavo ^a   Mortara, Renato Arruda ^b   de Andrade, Heitor Franco ^c   Reimão, Juliana Quero ^a  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biodistribution; Drug delivery; Furazolidone; Leishmania; Liposomes; Therapy

Indexed keywords

FURAZOLIDONE; LIPOSOME; MEGLUMINE ANTIMONATE; PENTAMIDINE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; BODY BURDEN; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DISEASE MODEL; DRUG COST; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SELECTIVITY; ENCAPSULATION; FEMALE; HAMSTER; IC 50; LEISHMANIA CHAGASI; LIVER; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; SPLEEN; VISCERAL LEISHMANIASIS;

EID: 77953812602     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.04.006     Document Type: Article

References (15)

1. Croft S.L., Snowdon D., Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996, 38:1041-1047.
2. Berman J.D., Lee L.S. Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 1983, 32:947-951.
3. Neal R.A., van Bueren J., Hooper G. The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo. Ann Trop Med Parasitol 1988, 82:453-456.
4. Llovet T., Sánchez F., Mirelis B., Prats G. Sensitivity of enteropathogenic bacteria to furazolidone. Enferm Infecc Microbiol Clin 1990, 8:449-452.
5. Wright J.M., Dunn L.A., Upcroft P., Upcroft J.A. Efficacy of antigiardial drugs. Expert Opin Drug Saf 2003, 2:529-541.
6. Nicoletti S., Seifert K., Gilbert I.H. N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents 2009, 33:441-448.
7. Tempone A.G., Perez D., Rath S., Vilarinho A.L., Mortara R.A., Andrade H.F.J. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 2004, 54:60-68.
8. Stauber L.A., Franchino E.M., Grun J. An 8-day method for screening compounds against Leishmania donovani in the golden hamster. J Protozool 1958, 5:269-273.
9. Sartorelli P., Andrade S.P., Melhem M.S., Prado F.O., Tempone A.G. Isolation of antileishmanial sterol from the fruits of Cassia fistula using bioguided fractionation. Phytother Res 2007, 7:644-647.
10. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986, 93:157-165.
11. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1980, 75:4194-4198.
12. Stewart J.C.M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980, 104:10-14.
13. Bradley D.J., Kirkley J. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin Exp Immunol 1977, 30:119-129.
14. Helming L., Winter J., Gordon S. The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion. J Cell Sci 2009, 122:453-459.
15. Zolnik B.S., Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 2009, 61:422-427.